Trulicity label summary, SPL effective June 16, 2026 (read November 8, 2026)
ItemLabel
UsesBlood sugar control in type 2 diabetes (adults and ages 10+); lower risk of CV death, heart attack or stroke in adults with type 2 diabetes and heart disease or multiple CV risk factors
ScheduleOnce weekly injection
Adult doses0.75 mg start; 1.5 mg after 4 weeks if needed; then 1.5 mg steps at least 4 weeks apart to 3 mg and 4.5 mg
Pediatric doses0.75 mg start; maximum 1.5 mg
FormSingle-dose pens: 0.75, 1.5, 3, 4.5 mg
First approvedSeptember 18, 2014

What is Trulicity used for?

Trulicity treats type 2 diabetes. It improves blood sugar alongside diet and exercise in adults and in children 10 and older.

It also carries a cardiovascular indication that is broader than some in the class: adults with type 2 diabetes who have established heart disease or multiple cardiovascular risk factors. That wording reflects the REWIND trial, which enrolled both groups. More on the class and heart outcomes: GLP-1 drugs and cardiovascular risk.

Is Trulicity approved for weight loss?

No. Trulicity has no weight-management indication, and none of its label uses mention weight. People seeking a GLP-1 for weight are usually prescribed a product with that label, such as Wegovy, Zepbound, Saxenda or Foundayo. See the GLP-1 medications hub for which brands carry which labels.

How is Trulicity dosed?

Adults start at 0.75 mg once weekly. After 4 weeks the dose may go to 1.5 mg, and further increases come in 1.5 mg steps after at least 4 weeks on each dose, up to 4.5 mg.

Children start at the same 0.75 mg and can go up to 1.5 mg after at least 4 weeks. The gradual increases are meant to reduce stomach and bowel side effects. Your prescriber decides whether you need more than the starting dose.

Trulicity can be injected at any time of day, with or without food, in the abdomen, thigh or upper arm. If you miss a dose, the label says to take it as soon as possible if at least 3 days (72 hours) remain before the next scheduled dose; otherwise skip it and keep your usual day. The injection day can change as long as the last dose was at least 3 days earlier. If you also use insulin, the two go in as separate injections and are never mixed.

What did the REWIND trial show?

REWIND randomized 9,901 adults aged 50 or older with type 2 diabetes and either prior cardiovascular disease or risk factors to Trulicity 1.5 mg or placebo. Over a median 5.4 years, the composite of heart attack, stroke or cardiovascular death occurred in 12.0% on Trulicity versus 13.4% on placebo, a hazard ratio of 0.88 (95% CI 0.79 to 0.99).

The published paper notes that all-cause death did not differ significantly between groups, and that 47.4% on dulaglutide reported a stomach or bowel adverse event versus 34.1% on placebo over the trial.

Trulicity later served as the comparator in SURPASS-CVOT, where tirzepatide (Mounjaro) was shown non-inferior to dulaglutide 1.5 mg for major cardiovascular events, without showing superiority. That trial is covered on the Mounjaro page.

What side effects does the label list?

In the label's pooled placebo-controlled adult trials, nausea occurred in 12.4% on 0.75 mg and 21.1% on 1.5 mg, versus 5.3% on placebo. Vomiting and diarrhea were also more common than on placebo.

Like every GLP-1 receptor agonist on this site, Trulicity carries a boxed warning for thyroid C-cell tumors seen in rodents. It should not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2. The label also warns about pancreatitis, low blood sugar with insulin or sulfonylureas, allergic reactions, kidney injury from dehydration, severe stomach and bowel effects, diabetic eye complications and gallbladder disease.

Is there a generic or compounded dulaglutide?

Trulicity is licensed as a biologic (BLA 125469). When we checked Drugs@FDA on November 8, 2026, it was the only dulaglutide product listed. Our compounded price table tracks only semaglutide and tirzepatide programs, and dulaglutide is not part of FDA's April 2026 503B bulks proposal, which named semaglutide, tirzepatide and liraglutide. For the daily alternative with generics, see liraglutide.

Frequently asked questions

Can Trulicity be used for weight loss?

Trulicity's FDA label covers type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes; it has no weight-management indication. Any weight change is not an approved use. People seeking a GLP-1 for weight are typically prescribed a product with a weight label, such as Wegovy, Zepbound, Saxenda or Foundayo, and insurance usually follows the label.

What is the highest dose of Trulicity?

For adults, the label's maximum is 4.5 mg once weekly, reached in 1.5 mg steps from 1.5 mg with at least 4 weeks on each dose. Treatment starts at 0.75 mg. For children 10 and older, the maximum is 1.5 mg weekly. Pens come in 0.75, 1.5, 3 and 4.5 mg single-dose strengths.

Does Trulicity lower heart attack risk?

In REWIND, 9,901 adults with type 2 diabetes and heart disease or risk factors took Trulicity 1.5 mg or placebo for a median 5.4 years. Heart attack, stroke or cardiovascular death occurred in 12.0% versus 13.4%, a hazard ratio of 0.88. That result supports Trulicity's cardiovascular indication for adults with type 2 diabetes.

How does Trulicity compare with Mounjaro?

SURPASS-CVOT compared them directly in 13,299 adults with type 2 diabetes and heart disease over a median 210.1 weeks. Mounjaro up to 15 mg was non-inferior to Trulicity 1.5 mg for major cardiovascular events, with a hazard ratio of 0.92, but superiority was not established, per the Mounjaro label revised August 2026.

How often is Trulicity injected?

Once a week, using a single-dose pen, per the label. That puts it alongside Ozempic, Mounjaro, Wegovy and Zepbound as a weekly drug, unlike liraglutide (Victoza and Saxenda), which is injected daily. If a dose is missed, the label says to take it if at least 3 days remain before the next one, and otherwise to skip it.

Sources

  1. FDA label (DailyMed): Trulicity prescribing information — SPL effective June 16, 2026 (DailyMed version August 10, 2026); sections 1, 2, 3, 6.1, 14 read 2026-11-08
  2. Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet 2019;394:121-130 — published July 13, 2019; abstract read 2026-11-08
  3. Drugs@FDA: Trulicity (BLA 125469) — original approval September 18, 2014; queried 2026-11-08
  4. FDA label (DailyMed): Mounjaro prescribing information (SURPASS-CVOT) — label revised August 2026; section 14.6 read 2026-11-08

Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.

Check NexLife's plans and state availability → See the price index

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.